COSM · Cosmos Health Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.93M | - | $17.11M | $14.75M | $13.71M | - | $12.41M | $13.21M | $14.58M | - |
| Cost of Revenue | $16.55M | - | $14.51M | $13.58M | $11.66M | - | $11.20M | $12.44M | $13.25M | - |
| Gross Profit | $1.38M | - | $2.60M | $1.16M | $2.05M | - | $1.21M | $767.2K | $1.33M | - |
| R&D | $0 | - | $0 | $0 | $0 | - | - | - | - | - |
| SG&A | $1.80M | - | $2.04M | $1.49M | $1.48M | - | $1.78M | $1.39M | $1.42M | - |
| Total Operating Expenses | $3.57M | - | $4.42M | $3.81M | $2.88M | - | $3.45M | $3.27M | $3.17M | - |
| D&A | $315.8K | - | $377.9K | $353.9K | $320.4K | - | $304.1K | $313.1K | $312.3K | - |
| Operating Income | ($2.18M) | - | ($1.82M) | ($2.65M) | ($833.1K) | - | ($2.24M) | ($2.50M) | ($1.84M) | - |
| Interest Expense | $423.2K | - | $669.1K | $388.8K | $187.1K | - | $181.4K | $342.4K | $168.7K | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($2.81M) | - | ($5.35M) | ($2.83M) | ($818.1K) | - | ($2.18M) | ($2.59M) | ($1.87M) | - |
| EPS - Basic | ($0.06) | - | ($0.17) | ($0.10) | ($0.03) | - | ($0.45) | ($0.15) | ($0.11) | - |
| EPS - Diluted | ($0.06) | - | ($0.17) | ($0.10) | ($0.03) | - | ($0.45) | ($0.15) | ($0.11) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $514.7K | $715.7K | $315.1K | $655.5K | $742.9K | $315.1K | $3.31M | $343.5K | $865.1K | $3.83M |
| Accounts Receivable | $18.19M | $19.63M | $18.03M | $15.46M | $14.25M | $13.48M | $17.48M | $18.38M | $19.07M | $19.76M |
| Inventory | $5.65M | $5.78M | $5.68M | $5.11M | $4.74M | $4.36M | $4.89M | $4.32M | $4.87M | $4.79M |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $36.89M | $38.39M | $38.10M | $30.56M | $27.84M | $25.46M | $36.24M | $33.42M | $34.29M | $36.61M |
| Total Assets | $62.37M | $65.48M | $69.49M | $61.84M | $57.19M | $54.31M | $64.52M | $60.83M | $62.35M | $66.01M |
| Current Liabilities | $34.08M | $38.27M | $38.53M | $31.17M | $26.59M | $25.76M | $25.21M | $24.82M | $23.56M | $24.32M |
| Long-term Debt | $3.45M | $3.78M | $5.37M | $5.19M | $4.85M | $4.11M | $4.27M | $3.93M | $1.33M | $4.61M |
| Total Liabilities | $42.54M | $47.05M | $46.36M | $35.60M | $31.24M | $29.78M | $29.54M | $28.71M | $27.80M | $29.97M |
| Stockholders' Equity | $19.83M | $18.42M | $23.13M | $26.23M | $25.95M | $24.53M | $34.98M | $32.12M | $34.55M | $36.04M |
| Retained Earnings | ($135.97M) | ($133.17M) | ($123.02M) | ($117.67M) | ($114.84M) | ($114.02M) | ($104.48M) | ($96.10M) | ($93.51M) | ($91.64M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.07M) | - | - | - | ($186.3K) | - | - | - | ($3.41M) | - |
| Investing Cash Flow | ($709.0K) | - | - | - | ($7.1K) | - | - | - | $126.5K | - |
| Financing Cash Flow | $347.6K | - | - | - | $560.9K | - | - | - | $206.9K | - |
| CapEx | $11.4K | - | - | - | $12.5K | - | - | - | $82.7K | - |
| Free Cash Flow | ($1.08M) | - | - | - | ($198.8K) | - | - | - | ($3.49M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 7.7% | - | 15.2% | 7.9% | 14.9% | - | 9.7% | 5.8% | 9.1% | - |
| Operating margin | -12.2% | - | -10.6% | -17.9% | -6.1% | - | -18.0% | -18.9% | -12.6% | - |
| EBITDA margin | -10.4% | - | -8.4% | -15.5% | -3.7% | - | -15.6% | -16.6% | -10.4% | - |
| Net margin | -15.6% | - | -31.3% | -19.2% | -6.0% | - | -17.6% | -19.6% | -12.8% | - |
| Free cash flow margin | -6.0% | - | - | - | -1.5% | - | - | - | -24.0% | - |
| FCF / Net income | 0.38 | - | - | - | 0.24 | - | - | - | 1.87 | - |
| R&D / Revenue | 0.0% | - | 0.0% | 0.0% | 0.0% | - | - | - | - | - |
| SG&A / Revenue | 10.0% | - | 11.9% | 10.1% | 10.8% | - | 14.4% | 10.5% | 9.7% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -4.5% | - | -7.7% | -4.6% | -1.4% | - | -3.4% | -4.3% | -3.0% | - |
| Return on equity | -14.1% | - | -23.1% | -10.8% | -3.2% | - | -6.2% | -8.1% | -5.4% | - |
| Return on invested capital | -7.4% | - | -5.0% | -6.7% | -2.1% | - | -4.5% | -5.5% | -4.0% | - |
| Liquidity | ||||||||||
| Current ratio | 1.08 | 1.00 | 0.99 | 0.98 | 1.05 | 0.99 | 1.44 | 1.35 | 1.46 | 1.51 |
| Quick ratio | 0.92 | 0.85 | 0.84 | 0.82 | 0.87 | 0.82 | 1.24 | 1.17 | 1.25 | 1.31 |
| Cash ratio | 0.02 | 0.02 | 0.01 | 0.02 | 0.03 | 0.01 | 0.13 | 0.01 | 0.04 | 0.16 |
| Leverage | ||||||||||
| Debt / Equity | 0.17 | 0.20 | 0.23 | 0.20 | 0.19 | 0.17 | 0.12 | 0.12 | 0.04 | 0.13 |
| Debt / Assets | 0.06 | 0.06 | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 | 0.06 | 0.02 | 0.07 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -5.2x | - | -2.7x | -6.8x | -4.5x | - | -12.3x | -7.3x | -10.9x | - |
| Equity multiplier | 3.15 | 3.55 | 3.00 | 2.36 | 2.20 | 2.21 | 1.84 | 1.89 | 1.80 | 1.83 |
| Liabilities / Assets | 0.68 | 0.72 | 0.67 | 0.58 | 0.55 | 0.55 | 0.46 | 0.47 | 0.45 | 0.45 |
| Efficiency | ||||||||||
| Asset turnover | 0.29 | - | 0.25 | 0.24 | 0.24 | - | 0.19 | 0.22 | 0.23 | - |
| Inventory turnover | 2.93 | - | 2.55 | 2.66 | 2.46 | - | 2.29 | 2.88 | 2.72 | - |
| Days sales outstanding | 370d | - | 385d | 383d | 379d | - | 514d | 508d | 477d | - |
| Days inventory outstanding | 125d | - | 143d | 137d | 148d | - | 159d | 127d | 134d | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.8x | - | 1.5x | 0.3x | 0.4x | - | 0.5x | - | 0.3x | - |
| P / S | 0.8x | - | 2.0x | 0.5x | 0.8x | - | 1.3x | - | 0.8x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 30.7% | - | 37.9% | 11.7% | -6.0% | - | -3.2% | 6.8% | 18.1% | - |
| Revenue CAGR (3y) | 13.2% | - | 12.5% | 3.7% | 1.6% | - | -3.0% | -3.8% | 7.9% | - |
| Revenue CAGR (5y) | 9.1% | - | 3.6% | 2.8% | 2.8% | - | 5.1% | 9.2% | 8.5% | - |
| Gross profit growth (YoY) | -32.6% | - | 115.7% | 51.7% | 53.7% | - | -0.7% | -19.0% | 39.3% | - |
| Operating income growth (YoY) | -162.2% | - | 18.8% | -5.7% | 54.6% | - | 25.8% | 2.9% | 30.7% | - |
| Net income growth (YoY) | -242.9% | - | -145.3% | -9.2% | 56.2% | - | 34.8% | -163.9% | -305.9% | - |
| EPS growth (YoY) | -100.0% | - | 62.2% | 33.3% | 72.7% | - | -66.7% | -66.7% | -175.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -442.4% | - | - | - | 94.3% | - | - | - | 45.1% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -23.6% | -24.9% | -33.9% | -18.3% | -24.9% | -31.9% | -20.9% | -26.4% | -21.5% | -8.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$65.27M totalWholesale$59.32M · 90.9%
Nutraceuticals And Pharmaceuticals$4.26M · 6.5%
Pharmamanufacturing$1.69M · 2.6%
Other$1.2K · 0.0%
Peer comparison
Same SIC group: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Comparing Cosmos Health Inc. against the 5 most active filers in the same SIC group.